Edgewise Therapeutics (EWTX) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Edgewise Therapeutics (NASDAQ: EWTX) recently:

• 6/2/2026 – Edgewise Therapeutics had its price target lowered by Royal Bank Of Canada from $50.00 to $48.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Edgewise Therapeutics had its price target raised by HC Wainwright from $42.00 to $45.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Edgewise Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $66.00 price target on the stock.
• 6/1/2026 – Edgewise Therapeutics had its price target raised by Wedbush from $46.00 to $52.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Edgewise Therapeutics was given a new $52.00 price target by Truist Financial Corporation.
• 4/20/2026 – Edgewise Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 50,000 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the chief marketing officer owned 4,367 shares of the company’s stock, valued at $168,435.19. The trade was a 91.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 83,892 shares of company stock worth $3,018,216. 21.30% of the stock is owned by insiders.

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.